Related Experiment Video
Updated: Dec 31, 2025
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet
Boris Schnorbus1,2, Andreas Daiber1,3, Kerstin Jurk2
1Zentrum für Kardiologie, Kardiologie I, Universitätsmedizin Mainz, Johannes Gutenberg-University Mainz, Langenbeckstraße 1, 55131 Mainz, Germany.
Insights
Prasugrel improved endothelial function and reduced inflammation after stenting for acute coronary syndrome, unlike clopidogrel or ticagrelor when given before the procedure. This benefit was lost if medication was given after stenting.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Interventional Cardiology
Background:
- Acute coronary syndromes (ACS) often require percutaneous coronary intervention (PCI) with stenting.
- Antiplatelet therapy is crucial post-PCI, with P2Y12 inhibitors like clopidogrel, prasugrel, and ticagrelor being standard.
- Endothelial dysfunction and inflammation are key factors in ACS and post-PCI outcomes.
Purpose of the Study:
- To compare the effects of clopidogrel, prasugrel, and ticagrelor on peripheral endothelial function in ACS patients undergoing stenting.
- To assess the impact of these P2Y12 inhibitors on inflammatory markers and platelet aggregation.
Main Methods:
- A randomized, parallel, blinded study involving 90 ACS patients undergoing stenting.
- Primary endpoint: change in flow-mediated dilation (FMD) post-stenting.
- Secondary endpoints: plasma IL-6 levels and platelet aggregation, assessed in relation to drug administration timing (pre- vs. post-stenting).
Main Results:
- All three drugs improved FMD before stenting; however, stenting blunted FMD with clopidogrel and ticagrelor, but not prasugrel.
- Prasugrel demonstrated superior improvement in FMD compared to clopidogrel and ticagrelor when administered 2 hours before stenting.
- Prasugrel also showed lower IL-6 levels and reduced platelet aggregation compared to the other agents.
Conclusions:
- Prasugrel therapy is associated with improved endothelial function, enhanced platelet inhibition, and reduced IL-6 levels in ACS patients undergoing stenting, particularly when given pre-procedure.
- These findings suggest potential prognostic benefits of prasugrel over ticagrelor and clopidogrel.
- The timing of P2Y12 inhibitor administration (pre- vs. post-stenting) significantly influences its effect on endothelial function.
Aims:
In a randomized, parallel, blinded study, we investigate the impact of clopidogrel, prasugrel, or ticagrelor on peripheral endothelial function in patients undergoing stenting for an acute coronary syndrome.
Methods And Results:
The primary endpoint of the study was the change in endothelium-dependent flow-mediated dilation (FMD) following stenting. A total of 90 patients (age 62 ± 9 years, 81 males, 22 diabetics, 49 non-ST elevation myocardial infarctions) were enrolled. There were no significant differences among groups in any clinical parameter. Acutely before stenting, all three drugs improved FMD without differences between groups (P = 0.73). Stenting blunted FMD in the clopidogrel and ticagrelor group (both P < 0.01), but not in the prasugrel group. During follow-up, prasugrel was superior to clopidogrel [mean difference 2.13, 95% confidence interval (CI) 0.68-3.58; P = 0.0047] and ticagrelor (mean difference 1.57, 95% CI 0.31-2.83; P = 0.0155), but this difference was limited to patients who received the study therapy 2 h before stenting. Ticagrelor was not significantly superior to clopidogrel (mean difference 0.55, 95% CI -0.73 to 1.82; P = 0.39). No significant differences were seen among groups for low-flow-mediated dilation. Plasma interleukin (IL)-6 (P = 0.02 and P = 0.01, respectively) and platelet aggregation reactivity in response to adenosine diphosphate (P = 0.002 and P = 0.035) were lower in the prasugrel compared to clopidogrel and ticagrelor group.
Conclusion:
As compared to ticagrelor and clopidogrel, therapy with prasugrel in patients undergoing stenting for an acute coronary syndrome is associated with improved endothelial function, stronger platelet inhibition, and reduced IL-6 levels, all of which may have prognostic implications. This effect was lost in patients who received the study medication immediately after stenting.
Eudract-No:
2011-005305-73.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Acute Coronary Syndrome I: Introduction